维布妥昔单抗联合纳武利尤单抗一线治疗老年或不适合化疗的霍奇金淋巴瘤:多中心单臂2期ACCRU试验
这项多中心单臂2期试验评估维布妥昔单抗联合纳武利尤单抗一线治疗老年(≥60岁)或不适合标准化疗的经典霍奇金淋巴瘤患者。共纳入46例,8周期后总缓解率为61%(95%CI 45-75),完全代谢缓解率48%。虽然未达到预设活性标准,但方案在多数患者中耐受良好。
要点
- 维布妥昔单抗联合纳武利尤单抗在老年或不适合化疗的霍奇金淋巴瘤中总缓解率61%,完全代谢缓解率48%。
- 48%患者出现周围神经病变,11%为3级;30%患者因神经毒性等调整剂量。
- 1例(2%)患者死于心脏骤停,可能与治疗相关。
核心结论
- 尽管未达到预设活性标准,维布妥昔单抗联合纳武利尤单抗在老年或不适合化疗的初治霍奇金淋巴瘤患者中具有活性且多数耐受良好。
研究设计与样本
- 多中心、单臂、2期试验,在美国8个癌症中心开展,共纳入46例初治经典霍奇金淋巴瘤患者。
- 入组条件:年龄≥60岁,或<60岁但不适合标准ABVD化疗(心脏射血分数<50%、肺弥散功能<80%、肌酐清除率30-<60 mL/min或拒绝化疗),ECOG体能状态0-2。
- 主要终点:8周期治疗结束时的总缓解(部分代谢缓解或完全代谢缓解)。
主要发现
- interim分析时前25例可评估患者总缓解率64%(95%CI 43-82;16/25),其中完全代谢缓解13例(52%),部分代谢缓解3例(12%)。
- 全部46例可评估患者中,完全代谢缓解22例(48%),部分代谢缓解6例(13%),总缓解率61%(95%CI 45-75)。
- 14例(30%)患者共发生16次剂量调整,主要因神经毒性;22例(48%)出现周围神经病变,其中5例(11%)为3级。
- 4级不良事件包括转氨酶升高1例(2%)、脂肪酶或淀粉酶升高2例(4%)、胰腺炎1例(2%);1例(2%)死于心脏骤停,可能与治疗相关。
关键数值与推荐
- 总缓解率61%(95%CI 45-75),完全代谢缓解率48%。
临床怎么用
- 对于老年或不适合标准ABVD化疗的初治霍奇金淋巴瘤患者,维布妥昔单抗联合纳武利尤单抗可作为去化疗策略的候选方案。
- 治疗中需密切监测周围神经病变,必要时调整剂量。
局限性
- 单臂设计,无对照组。
- 未达到预设活性标准,试验提前终止入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hodgkin lymphoma is potentially curable. However, 15-35% of older patients (ie, >60 years) have a lower response rate, worse survival outcomes, and greater toxicity than younger patients. Brentuximab vedotin and nivolumab exhibit activity in patients with relapsed or refractory Hodgkin lymphoma. We therefore aimed to evaluate the safety and efficacy of brentuximab vedotin and nivolumab in untreated older patients with Hodgkin lymphoma or in younger patients considered unsuitable for standard ABVD (ie, doxorubicin, bleomycin, vinblastine, and dacarbazine) therapy. METHODS: We did a multicentre, single-arm, phase 2 trial at eight cancer centres in the USA. Previously untreated patients with classic Hodgkin lymphoma were eligible for study enrolment if they were 60 years or older, or younger than 60 years but considered unsuitable for standard chemotherapy because of a cardiac ejection fraction of less than 50%, pulmonary diffusion capacity of less than 80%, or a creatinine clearance of 30 mL/min or more but less than 60 mL/min, or those who refused chemotherapy. Patients were also required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients received brentuximab vedotin at 1·8 mg/kg (dose cap at 180 mg) and nivolumab at 3 mg/kg both intravenously every 21 days for 8 cycles. The primary endpoint was the overall response, defined as a partial metabolic response or complete metabolic response at the end of 8 cycles of treatment. A per protocol analysis was done including all patients who received treatment in the activity and safety analyses. This study is registered with ClinicalTrials.gov, number NCT02758717. FINDINGS: Between May 13, 2016, and Jan 30, 2019, the study accrued 46 patients. The median age was 71·5 years (IQR 64-77), with two (4%) of 46 patients younger than 60 years. Median follow-up was 21·2 months (IQR 15·6-29·9), and 35 (76%) of 46 patients completed all 8 cycles of therapy. At the interim analysis on Oct 11, 2019, the first 25 evaluable patients had an overall response rate of 64% ([95% CI 43-82] 16 of 25 patients; 13 [52%] had a complete metabolic response and three [12%] had a partial metabolic response). The trial was closed to accrual on Oct 14, 2019, after the interim analysis failed to meet the predefined criteria. In all 46 evaluable patients, 22 (48%) patients achieved a complete metabolic response and six (13%) achieved a partial metabolic response (overall response rate 61% [95% CI 45-75]). 14 (30%) of 46 patients had 16 dose adjustments, primarily due to neurotoxicity. 22 (48%) of 46 patients had peripheral neuropathy (five [11%] patients had grade 3 peripheral neuropathy). Grade 4 adverse events included increased aminotranferases (one [2%] of 46), increased lipase or amylase (two [4%]), and pancreatitis (one [2%]). One (2%) patient died from cardiac arrest, possibly treatment related. INTERPRETATION: Although the trial did not meet the prespecified activity criteria, brentuximab vedotin plus nivolumab is active in older patients with previously untreated Hodgkin lymphoma with comorbidities. The regimen was also well tolerated in the majority of patients in this older population. Future trials should be based on optimising the dose and schedule, perhaps combined with other targeted agents that might permit chemotherapy-free strategies in older patients with Hodgkin lymphoma. FUNDING: Seattle Genetics and Bristol Myers Squibb.
引用
- Cheson BD, Bartlett NL, LaPlant B, et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2020. PMID: 33010817. doi:10.1016/S2352-3026(20)30275-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。